In November 2025 the FDA announced it would remove the boxed warning from menopausal hormone therapy products, and in February 2026 it approved label changes for the first six products. For clinics offering hormone therapy, this is the most significant labelling shift in two decades.
It is also being oversold. Here is what actually changed, and what did not.
What changed
The removal followed an FDA review of the scientific literature, an expert panel convened in July 2025, and a public comment period. On February 12, 2026 the FDA approved label changes to six menopausal hormone therapy products — spanning progestogen-only, systemic estrogen-only, topical vaginal estrogen, and combined systemic products.
The changes removed risk statements relating to cardiovascular disease, breast cancer, and probable dementia from the boxed warning. Labels are being rewritten with age-specific guidance reflecting evidence that women may see long-term benefit when therapy begins within about ten years of the onset of menopause.
The products in that first group were Prometrium, Divigel, Cenestin, Enjuvia, Estring and Bijuva.
What did not change
Three things, and each one matters commercially:
- The endometrial cancer boxed warning remains for products containing systemic estrogen alone. The boxed warning was not removed wholesale.
- Hormone therapy is still prescription-only, still requires evaluation, and still has contraindications. A labelling change is not a change in who is a candidate.
- Compounded hormone preparations are not FDA-approved products, and a label change to approved products says nothing about compounded ones. If your programme runs on compounded pellets or creams, this announcement did not validate them.
That third point is where the most aggressive marketing is happening, and it is the least defensible.
Why the change happened
The original boxed warning traced largely to the Women’s Health Initiative, whose findings were widely applied to populations and formulations the study did not really address — including younger women beginning therapy near the onset of menopause.
Two decades of reanalysis moved the clinical consensus toward a timing-dependent picture. The labelling has now caught up with that. It is a correction, not a declaration that hormone therapy is risk-free.
What it means for your marketing
| Do not say | Defensible version |
|---|---|
| “The FDA says HRT is safe” | “The FDA removed several risk statements from the boxed warning in 2026” |
| “No more warnings” | “An endometrial cancer warning remains for systemic estrogen-only products” |
| “FDA-approved bioidentical pellets” | Compounded preparations are not FDA-approved; say so |
| “Everyone should be on hormones” | “Candidacy depends on your history and timing; some patients are not candidates” |
| “Reverses aging” | Do not make it; it is unsupported |
A labelling change is a reason to have a better conversation with patients, not a licence to make claims the label still does not support.
What a good programme looks like
- Evaluation by a licensed provider, with candidacy genuinely assessed
- Baseline labs, and follow-up labs that actually change the plan
- A documented discussion of timing, benefits, and remaining risks
- Clarity with the patient about whether their preparation is FDA-approved or compounded
- A defined monitoring interval rather than open-ended refills
- A willingness to say no
The commercial opportunity, honestly framed
Demand for menopause care has risen sharply, and much of it is unmet. The labelling change will accelerate that. A clinic that can evaluate properly, monitor, and explain the evidence honestly is well positioned.
A clinic that markets on a misreading of the announcement is building on something a competitor, a board, or a plaintiff can dismantle in a sentence.
How MDside supports hormone programmes
The professional entity and licensed providers, protocols written to current labelling, lab integration including on-site draws, documented monitoring intervals, and pharmacy relationships where compounded preparations are clinically indicated — with the distinction between approved and compounded stated plainly to patients.
See what is included, or read about integrating lab draws.
Frequently asked questions
Did the FDA remove all warnings from hormone therapy?
No. Risk statements on cardiovascular disease, breast cancer and probable dementia were removed from the boxed warning on the first approved products, but the endometrial cancer boxed warning remains for systemic estrogen-only products.
When did this take effect?
The announcement came in November 2025; the FDA approved label changes for the first six products on February 12, 2026.
Does this apply to compounded hormones?
No. The change applies to approved products and their labelling. Compounded preparations are not FDA-approved and this announcement did not change that.
Can I now say hormone therapy is safe?
No. Describe what changed specifically. Candidacy still depends on individual history and timing, and some patients remain unsuitable.
Does this change who needs an evaluation?
Not at all. Hormone therapy remains prescription-only and requires evaluation by a licensed provider.
General information about labelling changes, not medical or legal advice, and not a treatment recommendation. Confirm current prescribing information for any specific product and consult healthcare counsel on marketing claims.